SCHEMBL25433232

SCHEMBL25433232

O[C@H]1[C@H](O)O[C@](CF)(COCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.36
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36
PDE4D Q08499 1/20 0.34
TACR1 P25103 1/20 0.33
PDPK1 O15530 1/20 0.32
MTOR P42345 1/20 0.32
GBA1 P04062 2/20 0.32
UGCG Q16739 2/20 0.32
GBA2 Q9HCG7 2/20 0.32
IDO1 P14902 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
BCHE P06276 3/20 0.31
ACHE P22303 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26135309 1.00 TSHR (0.36) TSHRGRM2GRM3PDE4DTACR1
SCHEMBL20819151 0.88 PDPK1 (0.37) TSHRGRM2GRM3PDE4DTACR1
SCHEMBL25432757 0.87 TSHR (0.36) TSHRGRM2GRM3PDE4DTACR1
SCHEMBL25433039 0.86 GRM2 (0.34) TSHRGRM2GRM3PDE4DTACR1
SCHEMBL26135760 0.86 GRM2 (0.35) TSHRGRM2GRM3PDE4DTACR1
SCHEMBL24120239 0.85 BCHE (0.34) TSHRGRM2GRM3PDE4DIDO1
SCHEMBL20819176 0.85 BCHE (0.34) TSHRGRM2GRM3PDE4DIDO1
SCHEMBL23922552 0.85 BCHE (0.34) TSHRGRM2GRM3PDE4DIDO1
SCHEMBL29546428 0.83 PDE4D (0.36) TSHRGRM2GRM3PDE4DTACR1
SCHEMBL8719016 0.80 PDPK1 (0.40) TSHRGRM2GRM3PDE4DTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. 2023-11-23 US disclosed
WO-2023178133-A9 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
WO-2023178133-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-09-21 WO disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 TSHR 3580/4885GRM2 526/4885GRM3 876/4885
US-20230374058-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 TSHR 3580/4885GRM2 526/4885GRM3 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.